MedTrace Logo

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

NCT05616728 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2024-08-19

Study results available
· View outcomes & findings →

Summary

Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.

Conditions

Interventions

DRUG

EDP-235

capsule

DRUG

Placebo

capsule

Sponsors & Collaborators

  • Enanta Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Enanta Pharmaceuticals, Inc · Enanta Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2023-02-08
Completion
2023-06-29
FDA Drug
Yes

Countries

  • United States
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05616728 on ClinicalTrials.gov